Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2025
2025
Date
Title
2025-05-21
Bonvadis topical cream received medical device marketing authorization approval for all indications in wounds for Australia.
>
2025-05-16
Oneness Biotech Co., Ltd. receives an United Arab Emirates patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).
>
2025-05-12
The Company’s 2025Q1 consolidated financial statements have been approved by the Board of Directors
>
2025-05-09
The medical device registration application of Bonvadis for all indications in wounds has been accepted by India CDSCO.
>
2025-04-30
News-Outstanding Corporate Governance Evaluation Results for the Microbio Group Microbio and Oneness Rank among Top 5% in the Corporate Governance Evaluation for Four Consecutive years; Diamond Biofund Enters Top 5% on Its First Evaluation
>
2025-04-23
The medical device registration application of Bonvadis for all indications in wounds has been accepted by Egypt EDA.
>
2025-04-21
Oneness announces information about the first investor conference in 2025.
>
2025-04-16
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Australia TGA
>
2025-04-10
Announcement for the Board of Directors’ resolution to dispose of (sublease) part of a right-of-use assets to a related party.
>
2025-04-10
Announcement for the Board of Directors’ resolution to acquire part of a right-of-use assets to a related party.
>
2025-04-10
Oneness has submitted 510(k) application of Bonvadis for full thickness wound indications to the U.S. FDA
>
2025-04-03
The medical device registration application of Bonvadis for all indications of wounds has been accepted by Brazil ANVISA.
>
2025-03-25
Oneness Biotech Co., Ltd., has been granted the Brazil Good Manufacturing Practice (B-GMP) certification for Bonvadis from Brazil ANVISA.
>
2025-03-18
The medical device registration application of Bonvadis for all indications in wounds has been accepted by UAE MOHAP
>
2025-02-27
Oneness Board of Directors resolved to convene the Annual Shareholders’ Meeting of 2025.
>
« Previous
1
2
3
Next »
